Total Payments
$145,977
2024 Payments
$36,421
Companies
9
Transactions
97
Medicare Patients
995
Medicare Billing
$156,922
Payment Breakdown by Category
Other$70,848 (48.5%)
Consulting$56,958 (39.0%)
Research$11,011 (7.5%)
Travel$5,298 (3.6%)
Food & Beverage$1,846 (1.3%)
Education$18.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,605 | 25 | 42.9% |
| Consulting Fee | $56,958 | 18 | 39.0% |
| Unspecified | $11,011 | 7 | 7.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,243 | 2 | 5.6% |
| Travel and Lodging | $5,298 | 19 | 3.6% |
| Food and Beverage | $1,846 | 25 | 1.3% |
| Education | $18.09 | 1 | 0.0% |
Payments by Type
General
$134,966
90 transactions
Research
$11,011
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $91,830 | 60 | $0 (2024) |
| Seagen Inc. | $18,173 | 8 | $0 (2023) |
| Celgene Corporation | $17,783 | 10 | $0 (2019) |
| PFIZER INC. | $16,685 | 7 | $0 (2024) |
| Amgen Inc. | $913.14 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $428.02 | 4 | $0 (2024) |
| BIOTRONIK INC. | $128.58 | 5 | $0 (2022) |
| Boston Scientific Corporation | $18.70 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $18.09 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,421 | 18 | Eisai Inc. ($18,556) |
| 2023 | $59,306 | 33 | Eisai Inc. ($40,935) |
| 2022 | $12,451 | 16 | EISAI INC. ($12,436) |
| 2021 | $12,658 | 10 | Eisai Inc. ($12,658) |
| 2020 | $7,245 | 6 | Eisai Inc. ($7,245) |
| 2019 | $12,694 | 10 | Celgene Corporation ($12,581) |
| 2018 | $442.00 | 1 | Celgene Corporation ($442.00) |
| 2017 | $4,760 | 3 | Celgene Corporation ($4,760) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $20.10 | General |
| Category: Oncology | ||||||
| 11/11/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,275.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $4,710.00 | General |
| Category: Oncology | ||||||
| 08/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $103.44 | General |
| 07/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2024 | Boston Scientific Corporation | LUX-Dx Insertable Cardiac Monitor (Device) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: LUX-Dx_CRM | ||||||
| 06/05/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $3,140.00 | General |
| Category: Oncology | ||||||
| 05/01/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 04/11/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,280.00 | General |
| Category: Oncology | ||||||
| 04/11/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,962.50 | General |
| Category: Oncology | ||||||
| 04/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $108.30 | General |
| Category: Oncology | ||||||
| 02/20/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 02/20/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $122.31 | General |
| Category: Oncology | ||||||
| 02/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $126.72 | General |
| 01/17/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| Category: Oncology | ||||||
| 01/16/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 01/16/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $667.62 | General |
| Category: Oncology | ||||||
| 01/04/2024 | Amgen Inc. | LUMAKRAS (Drug) | — | In-kind items and services | $913.14 | Research |
| Study: AMG 510 Ph1b Master Protocol 20190135 • Category: Oncology | ||||||
| 12/13/2023 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $8,635.00 | General |
| Category: Oncology | ||||||
| 12/13/2023 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $6,280.00 | General |
| Category: Oncology | ||||||
| 12/13/2023 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $120.55 | General |
| Category: Oncology | ||||||
| 10/27/2023 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $234.42 | General |
| Category: Oncology | ||||||
| 10/27/2023 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $207.19 | General |
| Category: Oncology | ||||||
| 10/27/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $51.97 | General |
| Category: Oncology | ||||||
| 10/27/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| nab1-paclitaxel (Abraxane) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, Phase 2 study (LAPACT). (ABI-007-PANC-007) | Celgene Corporation | $3,752 | 1 |
| ABI-007-PANC-007 | Celgene Corporation | $2,533 | 1 |
| ABI-007-NSCL-003 | Celgene Corporation | $1,156 | 1 |
| A phase 1, open-label, multicenter, safety study of nivolumab (bms-936558) in combination with nab-pacitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage iiib/iv non-small cell lung cancer or nab-paclitaxel in metastastic breast cancer (ABI-007-ST-001) | Celgene Corporation | $1,144 | 1 |
| ABI-007-PANC-003 | Celgene Corporation | $1,071 | 1 |
| AMG 510 Ph1b Master Protocol 20190135 | Amgen Inc. | $913.14 | 1 |
| ABI-007-ST-001 - A phase 1, open-label, multicenter, safety study of nivolumab (bms-936558) in combination with nab-pacitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage iiib/iv | Celgene Corporation | $442.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 281 | 504 | $275,404 | $48,356 |
| 2022 | 5 | 243 | 470 | $234,505 | $39,518 |
| 2021 | 7 | 276 | 505 | $213,191 | $42,840 |
| 2020 | 6 | 195 | 364 | $134,919 | $26,208 |
Total Patients
995
Total Services
1,843
Medicare Billing
$156,922
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 92 | 210 | $146,790 | $24,228 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 61 | 99 | $49,698 | $7,373 | 14.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 58 | $22,678 | $5,744 | 25.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 33 | 33 | $28,116 | $4,828 | 17.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 27 | $7,023 | $1,778 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 30 | $10,620 | $1,593 | 15.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $5,937 | $1,188 | 20.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 11 | 14 | $2,254 | $1,052 | 46.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 17 | 22 | $2,288 | $572.65 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 92 | 230 | $111,884 | $17,334 | 15.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 87 | $32,421 | $7,296 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 44 | 44 | $36,545 | $6,349 | 17.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 39 | 49 | $32,959 | $5,453 | 16.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 43 | 60 | $20,696 | $3,087 | 14.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 86 | 164 | $70,667 | $13,219 | 18.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 61 | 112 | $63,980 | $12,998 | 20.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 86 | $28,842 | $7,390 | 25.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 31 | 31 | $23,941 | $4,795 | 20.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 46 | 64 | $19,149 | $3,080 | 16.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 14 | 28 | $2,912 | $754.36 | 25.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 17 | 20 | $3,700 | $603.60 | 16.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 78 | 168 | $59,448 | $9,871 | 16.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 34 | 66 | $31,050 | $6,145 | 19.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 58 | $18,966 | $5,121 | 27.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 24 | 24 | $15,952 | $3,257 | 20.4% |
About Edward Kim, M.D., PHD
Edward Kim, M.D., PHD is a Hematology & Oncology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1033237987.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Edward Kim, M.D., PHD has received a total of $145,977 in payments from pharmaceutical and medical device companies, with $36,421 received in 2024. These payments were reported across 97 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($62,605).
As a Medicare-enrolled provider, Kim has provided services to 995 Medicare beneficiaries, totaling 1,843 services with total Medicare billing of $156,922. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Sacramento, CA
- Active Since 03/27/2007
- Last Updated 09/05/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1033237987
Products in Payments
- Lenvima (Drug) $91,830
- TUKYSA (Drug) $34,858
- Abraxane (Drug) $17,783
- LUMAKRAS (Drug) $913.14
- TAGRISSO (Drug) $104.36
- LUX-Dx Insertable Cardiac Monitor (Device) $18.70
- KEYTRUDA (Biological) $18.09
- BIOMONITOR (Device) $15.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sacramento
Dr. Joseph Tuscano, M.d, M.D
Hematology & Oncology — Payments: $633,262
Hematology & Oncology $633,262
Adam Giermasz, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $518,605
Hematology & Oncology $518,605
Dr. David Gandara, M.d, M.D
Hematology & Oncology — Payments: $462,968
Hematology & Oncology $462,968
Dr. Scott Christensen, M.d, M.D
Hematology & Oncology — Payments: $391,606
Hematology & Oncology $391,606
Karen Kelly, M.d, M.D
Hematology & Oncology — Payments: $306,992
Hematology & Oncology $306,992
Paul Kaesberg, M.d, M.D
Hematology & Oncology — Payments: $221,939
Hematology & Oncology $221,939